A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome

doi:10.3748/wjg.v16.i5.547

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 5

This Article

(0)

(14698)

(57)

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

- Full Article with Cover (PDF)
- Full Article (XML)

Review

World J Gastroenterol. Feb 7, 2010; 16(5): 547-553
Published online Feb 7, 2010. doi: 10.3748/wjg.v16.i5.547

Full Size Figure Download Figure

Figure 2 Individual and pooled relative risk (A), heterogeneity indicators (B), and publication bias indicators (C) for the outcome of “global or clinical improvement” in the studies comparing mebeverine vs placebo therapy.

Citation: Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010; 16(5): 547-553
URL: https://www.wjgnet.com/1007-9327/full/v16/i5/547.htm
DOI: https://dx.doi.org/10.3748/wjg.v16.i5.547

Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010; 16(5): 547-553 [PMID: 20128021 DOI: 10.3748/wjg.v16.i5.547]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.